"During the pandemic, we have lost sight of long-term conditions that are the biggest contributors to worse outcomes", says prof. Hobbs. "We need to restart and catch up in CVD prevention ASAP."

The expert consensus pathway provides recommendations for the evaluation and management of adults with myocarditis and long COVID following COVID-19 infection.

A study shows that individuals in the post-acute phase of COVID-19 exhibited increased risks and 12-month burdens of incident CV diseases, compared to individuals with no evidence of SARA-CoV-2 infection.

A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

Anticoagulation after discharge may be necessary for a short time in patients who were hospitalized due to COVID-19 and have a high thrombotic risk, according to prof. Verheugt.

The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the NOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.

The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.

AHA 2021 As part of the ACTIV-4a study, it was examined whether use of P2Y12 inhibitors (ticagrelor or clopidogrel) changed the number of organ support-free days in a period of 28 days in non-critically ill hospitalized patients with COVID-19.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Is a therapeutic dose of heparin in COVID-19 patients more effective than standard dose heparin? Prof. ten Cate gives an update on the most recent findings.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.